Jonah Feldman

An investigational agent is planned for a phase 1 trial of patients with mantle cell lymphoma after preclinical data showed antitumor activity.

In an interview with Targeted Oncology, Benny Weksler, MD, MBA, reviews key trials that have recently influenced the standard of care for patients with stage IB to IIIB NSCLC.

In a first-in-human trial, a peptide-drug conjugate showed tolerability and antitumor activity in patients with advanced solid tumors.

At the 14th International Congress on Myeloproliferative Neoplasms, research into the case of dizygotic twins with essential thrombocythemia won the Best overall Abstract Award for concluding how their rare stem cell disorder was passed between both twins.

At the 14th International Congress on Myeloproliferative Neoplasms, Srdan Verstovsek, MD, PhD, reviewed the research supporting the optimal use of JAK inhibitors in patients with myelofibrosis.

A multicenter trial of the CAR T-cell product MB-106 has treated its first patient, Mustang Bio, Inc announced.

A survival benefit was elicited with the use of pemigatinib when used for patients with previously treated advanced cholangiocarcinoma who had an FGFR2 fusion or rearrangement.

Updated results from the L-MIND trial show continued efficacy and safety data for the combination of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.

Research now is addressing how subsequent therapies can meet needs of patients with Hodgkin lymphoma who progress after early lines of treatment.

Chimeric antigen receptor T-cell therapy provides a new option for patients with relapsed/refractory B-cell lymphoma.

Decision-making for the second to fourth lines of therapy in multiple myeloma can depend on many factors, and clinicians still face unanswered questions, according to Krina K. Patel, MD, MSc.

Celsion Corporation announced it had reached enrollment of 110 patients for the OVATION 2 trial of GEN-1 plus neoadjuvant chemotherapy for patients with advanced ovarian cancer.

Investigators for a phase 2 study of linperlisib began dosing its first patient with relapsed/refractory peripheral T/NK cell lymphoma.

For Thyroid Cancer Awareness Month, Warren C. Swegal, MD, highlights the changing landscape, important trials, sequencing, and future of this setting.

Trastuzumab deruxtecan at 5.4mg/kg demonstrated clinically meaningful benefit in patients with HER2-mutated non–small cell lung cancer.

The HCRN-GU16-260 trial reported results for patients with clear cell renal cell carcinoma who received frontline nivolumab followed by salvage nivolumab/ipilimumab on disease progression.

In an interview with Targeted Oncology, Jeffrey R. Schriber, MD, reviews advances in leukemia treatment for Leukemia Awareness Month.

A cohort of a clinical trial of the experimental agent STP705 successfully treated patients with cutaneous basal cell carcinomas, offering an alternative to surgery or other skin cancer treatment.

The PARP inhibitor rucaparib was shown to improve progression-free survival in a cohort of the ATLANTIS study platform for metastatic urothelial carcinoma.

The CoMMpass genomic data set of patients with multiple myeloma was utilized by investigators, contributing to 19 abstracts reported at the International Myeloma Society.

Updated analysis of the IKEMA trial showed the combination of isatuximab, carfilzomib, and dexamethasone to elicit superior progression-free survival vs carfilzomib and dexamethasone alone in patients with multiple myeloma.

In real-world patients with relapsed or refractory multiple myeloma, isatuximab-based regimens were found to be tolerable.

The novel targeted therapy abivertinib showed efficacy in a clinical trial of patients with EGFR T790M mutations who previously received an EGFR inhibitor.

Larotrectinib continued to demonstrate favorable efficacy and survival outcomes with low toxicity, according to extended follow-up for 2 trials of patients with lung cancer and NTRK fusions.

David L. Bartlett, MD, discussed the adoption of key immunotherapies and how exploration of the tumor microenvironment and immune environment is opening new approaches to treatment in an interview with Targeted Oncology.

Sophia Kamran, MD, discusses potential toxicities limiting the addition of immunotherapy to trimodal therapy for patients with urothelial cancer.

Following a study of frontline pembrolizumab plus axitinib or nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma, investigators recommended that prospective real-world studies are needed to confirm the results.

FOLFOXIRI plus panitumumab should not be recommended as upfront therapy for RAS and BRAF wild-type mCRC patients. according to investigators of the phase 3 TRIPLETE study.

The 5-year analysis of the CheckMate 227 study shows long-term survival benefit for nivolumab plus ipilimumab versus chemotherapy in patients with metastatic non–small cell lung cancer.

During an interview with Targeted Oncology, Shifeng S. Mao, MD, discussed what current and upcoming clinical studies have led to improvements in how physicians treat urothelial cancer.